Published in Neurotherapeutics on January 01, 2010
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
Animal models of traumatic brain injury. Nat Rev Neurosci (2013) 2.75
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci (2010) 2.40
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
Craniotomy: true sham for traumatic brain injury, or a sham of a sham? J Neurotrauma (2011) 1.49
Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice. PLoS One (2012) 1.36
New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation (2012) 1.34
Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury. J Neuroinflammation (2012) 1.33
Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat (2015) 1.31
Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br J Pharmacol (2011) 1.28
Morphological and genetic activation of microglia after diffuse traumatic brain injury in the rat. Neuroscience (2012) 1.21
Traumatic brain injury, neuroinflammation, and post-traumatic headaches. Headache (2013) 1.19
Attenuated inflammatory response in aged mice brains following stroke. PLoS One (2011) 1.14
Endocannabinoids and traumatic brain injury. Br J Pharmacol (2011) 1.14
CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by traumatic brain injury. J Neurosci (2015) 1.12
Traumatic Brain Injury pathophysiology and treatments: early, intermediate, and late phases post-injury. Int J Mol Sci (2013) 1.11
Microglia in the TBI brain: The good, the bad, and the dysregulated. Exp Neurol (2015) 1.10
Rod microglia: a morphological definition. PLoS One (2014) 1.10
Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends Pharmacol Sci (2015) 1.09
Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. PLoS One (2013) 1.06
Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. Inflammopharmacology (2013) 1.06
Low-level laser light therapy improves cognitive deficits and inhibits microglial activation after controlled cortical impact in mice. J Neurotrauma (2011) 1.06
Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem (2011) 1.04
Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-κB signaling pathway in experimental traumatic brain injury. J Neuroinflammation (2014) 1.04
High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. Front Neurol (2012) 1.04
Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone. J Neuroinflammation (2011) 1.02
Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. J Neurotrauma (2011) 1.01
Tumor necrosis factor alpha and Fas receptor contribute to cognitive deficits independent of cell death after concussive traumatic brain injury in mice. J Cereb Blood Flow Metab (2010) 1.00
Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury. J Cereb Blood Flow Metab (2012) 0.99
Understanding the neuroinflammatory response following concussion to develop treatment strategies. Front Cell Neurosci (2012) 0.99
The cytokine temporal profile in rat cortex after controlled cortical impact. Front Mol Neurosci (2012) 0.97
Analysis of functional pathways altered after mild traumatic brain injury. J Neurotrauma (2013) 0.96
Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury. Neurobiol Dis (2013) 0.96
Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation? Neurotherapeutics (2015) 0.94
Serum-based protein biomarkers in blast-induced traumatic brain injury spectrum disorder. Front Neurol (2012) 0.94
Long-lasting protection in brain trauma by endotoxin preconditioning. J Cereb Blood Flow Metab (2011) 0.93
Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatr Dis Treat (2015) 0.93
Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int (2011) 0.92
Transplantation of marrow stromal cells restores cerebral blood flow and reduces cerebral atrophy in rats with traumatic brain injury: in vivo MRI study. J Neurotrauma (2011) 0.92
Mitochondria-associated microRNAs in rat hippocampus following traumatic brain injury. Exp Neurol (2015) 0.91
Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury. J Neuroinflammation (2011) 0.91
Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation. PM R (2011) 0.91
Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes. J Neurotrauma (2014) 0.91
Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway. Sci Rep (2016) 0.91
Blood protein concentrations in the first two postnatal weeks associated with early postnatal blood gas derangements among infants born before the 28th week of gestation. The ELGAN Study. Cytokine (2011) 0.90
Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation (2012) 0.90
Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. J Neurotrauma (2014) 0.89
Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse. Brain Behav Immun (2015) 0.89
Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy. Neuropsychiatr Dis Treat (2015) 0.89
Anti-apoptotic and anti-oxidative roles of quercetin after traumatic brain injury. Cell Mol Neurobiol (2014) 0.88
Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis (2012) 0.88
Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury. Mediators Inflamm (2012) 0.88
Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol (2012) 0.88
Regional neurodegeneration and gliosis are amplified by mild traumatic brain injury repeated at 24-hour intervals. J Neuropathol Exp Neurol (2014) 0.87
Endogenous repair signaling after brain injury and complementary bioengineering approaches to enhance neural regeneration. Biomark Insights (2015) 0.87
Severe traumatic head injury affects systemic cytokine expression. J Am Coll Surg (2012) 0.86
Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor. J Cereb Blood Flow Metab (2013) 0.86
Pathophysiology of perinatal asphyxia: can we predict and improve individual outcomes? EPMA J (2011) 0.85
Diffuse brain injury induces acute post-traumatic sleep. PLoS One (2014) 0.84
Peroxisome proliferator activated receptor-γ and traumatic brain injury. Int J Clin Exp Med (2010) 0.84
Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury. J Neurosci Res (2012) 0.84
Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci (2015) 0.84
Granulocyte-macrophage colony-stimulating factor is neuroprotective in experimental traumatic brain injury. J Neurotrauma (2014) 0.84
IκBα deficiency in brain leads to elevated basal neuroinflammation and attenuated response following traumatic brain injury: implications for functional recovery. Mol Neurodegener (2012) 0.83
Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function. Acta Neuropathol Commun (2013) 0.83
Mild traumatic brain injury: is diffusion imaging ready for primetime in forensic medicine? Top Magn Reson Imaging (2010) 0.83
Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury. Br J Pharmacol (2015) 0.83
Neuroinflammation in animal models of traumatic brain injury. J Neurosci Methods (2016) 0.83
NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury. Brain Behav Immun (2016) 0.83
Preoperative mucosal tolerance to brain antigens and a neuroprotective immune response following surgical brain injury. J Neurosurg (2011) 0.82
A Decade of Research on TLR2 Discovering Its Pivotal Role in Glial Activation and Neuroinflammation in Neurodegenerative Diseases. Exp Neurobiol (2014) 0.82
Progesterone for neuroprotection in pediatric traumatic brain injury. Pediatr Crit Care Med (2015) 0.82
Environmental enrichment decreases asphyxia-induced neurobehavioral developmental delay in neonatal rats. Int J Mol Sci (2013) 0.82
Mean diffusivity in the amygdala correlates with anxiety in pediatric TBI. Brain Imaging Behav (2012) 0.82
Expression analysis of the early chemokine response 4 h after in vitro traumatic brain injury. Inflamm Res (2010) 0.82
Minocycline Transiently Reduces Microglia/Macrophage Activation but Exacerbates Cognitive Deficits Following Repetitive Traumatic Brain Injury in the Neonatal Rat. J Neuropathol Exp Neurol (2016) 0.82
Intranasal administration of human MSC for ischemic brain injury in the mouse: in vitro and in vivo neuroregenerative functions. PLoS One (2014) 0.81
Inflammation in acute CNS injury: a focus on the role of substance P. Br J Pharmacol (2015) 0.81
Mouse brain PSA-NCAM levels are altered by graded-controlled cortical impact injury. Neural Plast (2012) 0.81
Emerging Roles for the Immune System in Traumatic Brain Injury. Front Immunol (2016) 0.80
Increased expression of ferritin in cerebral cortex after human traumatic brain injury. Neurol Sci (2012) 0.80
Role of fibrinogen in cerebrovascular dysfunction after traumatic brain injury. Brain Inj (2013) 0.80
Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. Shock (2013) 0.80
The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice. Eur J Pharmacol (2015) 0.80
Temporal course of changes in gene expression suggests a cytokine-related mechanism for long-term hippocampal alteration after controlled cortical impact. J Neurotrauma (2014) 0.80
Design considerations of iron-based nanoclusters for noninvasive tracking of mesenchymal stem cell homing. ACS Nano (2014) 0.80
Midbrain raphe stimulation improves behavioral and anatomical recovery from fluid-percussion brain injury. J Neurotrauma (2012) 0.80
Tibial fracture exacerbates traumatic brain injury outcomes and neuroinflammation in a novel mouse model of multitrauma. J Cereb Blood Flow Metab (2015) 0.80
The Relationship Between Serum Levels of Interleukins 6, 8, 10 and Clinical Outcome in Patients With Severe Traumatic Brain Injury. Arch Trauma Res (2015) 0.79
Reactive oxygen species-activated nanoprodrug of Ibuprofen for targeting traumatic brain injury in mice. PLoS One (2013) 0.79
Osthole confers neuroprotection against cortical stab wound injury and attenuates secondary brain injury. J Neuroinflammation (2015) 0.79
Does enoxaparin interfere with HMGB1 signaling after TBI? A potential mechanism for reduced cerebral edema and neurologic recovery. J Trauma Acute Care Surg (2016) 0.79
Protective effect of Spatholobus suberectus on brain tissues in cerebral ischemia. Am J Transl Res (2016) 0.78
Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules. Regen Biomater (2015) 0.78
Ghrelin attenuates brain injury after traumatic brain injury and uncontrolled hemorrhagic shock in rats. Mol Med (2012) 0.78
Epigallocatechin-3-Gallate (EGCG) Attenuates Traumatic Brain Injury by Inhibition of Edema Formation and Oxidative Stress. Korean J Physiol Pharmacol (2015) 0.78
Hypertonic saline solution reduces the oxidative stress responses in traumatic brain injury patients. J Res Med Sci (2014) 0.78
The Fas death factor. Science (1995) 13.81
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest (1989) 10.59
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med (1998) 6.52
Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron (1999) 4.22
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Cytokines and acute neurodegeneration. Nat Rev Neurosci (2001) 3.70
Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet (2005) 3.70
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Pathophysiology of traumatic brain injury. Br J Anaesth (2007) 3.06
Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J (1995) 2.87
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ (2003) 2.74
Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev (1999) 2.57
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med (1990) 2.33
Cytokines and the nervous system. I: Expression and recognition. Trends Neurosci (1995) 2.28
Cell death mechanisms following traumatic brain injury. Brain Pathol (2004) 2.20
Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol (1989) 2.12
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci (2004) 2.08
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A (2006) 2.07
Interleukin-8 induces neutrophil transendothelial migration. Immunology (1991) 2.01
Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab (2009) 1.97
Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun (1995) 1.91
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab (2002) 1.88
Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol (1996) 1.84
Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit Care Med (2000) 1.82
Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull (1992) 1.80
Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J Cereb Blood Flow Metab (2000) 1.78
Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock (2001) 1.77
Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem (2002) 1.73
Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab (1996) 1.72
Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery (2001) 1.69
CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci (1999) 1.66
Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging (1996) 1.65
Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol (2006) 1.63
Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol (1991) 1.63
Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol (1992) 1.59
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol (2006) 1.55
Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci (1999) 1.55
Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol (2002) 1.51
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab (1994) 1.49
Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol (2004) 1.47
The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging (2001) 1.43
IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol (1999) 1.39
Cytokine actions in the central nervous system. Cytokine Growth Factor Rev (1999) 1.38
Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma (1997) 1.36
Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry (1997) 1.35
Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol (1993) 1.33
Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol (1999) 1.33
The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol (1998) 1.32
Annual review prize lecture cytokines - killers in the brain? J Physiol (1999) 1.31
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J (2005) 1.30
Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma (1994) 1.29
Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol (1993) 1.29
Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci (2007) 1.27
The neuroprotective role of inflammation in nervous system injuries. J Neurol (2004) 1.27
Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol (1998) 1.23
Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J Immunol (1999) 1.22
Experimental brain injury induces expression of interleukin-1 beta mRNA in the rat brain. Brain Res Mol Brain Res (1995) 1.17
Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci (1998) 1.17
Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J Neuroimmunol (2005) 1.16
Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci (2002) 1.15
Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur J Neurosci (2006) 1.15
A microdialysis method for the recovery of IL-1beta, IL-6 and nerve growth factor from human brain in vivo. J Neurosci Methods (2002) 1.14
Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol (1997) 1.14
Cell activation and inflammatory response following traumatic axonal injury in the rat. Neuroreport (2000) 1.10
Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice. Glia (2000) 1.09
IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci (1995) 1.08
Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J Neurosci Res (2000) 1.07
Proinflammatory cytokine, chemokine, and cellular adhesion molecule expression during the acute phase of experimental brain abscess development. Am J Pathol (2000) 1.06
Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock (1995) 1.06
Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res (1992) 1.04
Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci (1994) 1.04
Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: Distribution and time course of protein extravasation. J Neurotrauma (1992) 1.03
Opposite effects of interferon-gamma and prostaglandin E2 on tumor necrosis factor and interleukin-10 production in microglia: a regulatory loop controlling microglia pro- and anti-inflammatory activities. J Neurosci Res (1999) 1.01
Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat. J Cereb Blood Flow Metab (2000) 1.00
Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats. Exp Neurol (2006) 0.98
CXC-chemokines KC and macrophage inflammatory protein-2 (MIP-2) synergistically induce leukocyte recruitment to the central nervous system in rats. Immunol Lett (2003) 0.97
Potentiation of neurogenesis and angiogenesis by G-CSF after focal cerebral ischemia in rats. Brain Res (2007) 0.95
Acute excitotoxic injury induces expression of monocyte chemoattractant protein-1 and its receptor, CCR2, in neonatal rat brain. Exp Neurol (2000) 0.94
Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol (2002) 0.92
Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation. J Neuroimmunol (2005) 0.92
Cortical interleukin-1 beta elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery. Neurosci Lett (2000) 0.92
Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J Neurosci Res (2003) 0.91
Effects of interleukin-10 on neonatal excitotoxic brain lesions in mice. Brain Res Dev Brain Res (2003) 0.90
Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma (2005) 0.90
Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains. J Immunol (1995) 0.87
The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline. J Neural Transm (Vienna) (2008) 0.87
The initiation of the microglial response. Brain Pathol (2000) 0.86
Immunohistochemical characterization of Fas (CD95) and Fas Ligand (FasL/CD95L) expression in the injured brain: relationship with neuronal cell death and inflammatory mediators. Histol Histopathol (2007) 0.86
Leukocyte recruitment and the acute inflammatory response. Brain Pathol (2000) 0.86
Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury. J Neuroimmunol (1997) 0.82
Contribution of peripheral macrophages and microglia to the cellular reaction after mechanical or neurotoxin-induced lesions of the rat brain. Exp Neurol (1994) 0.80
Developmental expression of chemokine receptor genes in the human fetus. Early Hum Dev (2005) 0.79
Effect of interleukin-10 on newborn piglet brain following hypoxia-ischemia and endotoxin-induced inflammation. Biol Neonate (2005) 0.78
The role of markers of inflammation in traumatic brain injury. Front Neurol (2013) 2.01
Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab (2009) 1.97
In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma (2010) 1.35
The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury. J Cereb Blood Flow Metab (2004) 0.96
Attenuated neurological deficit, cell death and lesion volume in Fas-mutant mice is associated with altered neuroinflammation following traumatic brain injury. Brain Res (2011) 0.95
Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol (2002) 0.92
Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation (2014) 0.90
Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. J Neurotrauma (2014) 0.89
Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury. Mediators Inflamm (2012) 0.88
Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury. J Neuroinflammation (2004) 0.84